Dec
19
Valeant Investment Finally Pays Off For Bill Ackman
By
No, the embattled pharmaceutical company hasn’t stopped hemorrhaging losses, figured out how to sell female orgasms, learned that there is such a thing as bad news, or begun to change investors’ rock-bottom perceptions of it. But its contribution to Pershing Square’s 2016 is not purely an intangible one, like a hard-won lesson or a promise to stop burning holes in its shareholders’ stomachs. Nope: Valeant is generating some actual value for Pershing Square investors this month, albeit probably not how Ackman drew it up…
Valeant Investment Finally Pays Off For Bill Ackman
